title: Imatinib and ruxolitinib association: first experience in two patients.
authors.affiliation: Oncohematology Unit of the Elderly, Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Milan, Italy Hematopathology Service, Division of Pathology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Milan, Italy Division of Hematology, Santa Croce e Carle Hospital, Cuneo, Italy Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy aiurlo@policlinico.mi.it.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Iurlo
authors.affiliation: Hematopathology Service, Division of Pathology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Milan, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Gianelli
authors.affiliation: Division of Hematology, Santa Croce e Carle Hospital, Cuneo, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Rapezzi
authors.affiliation: Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Cattaneo
authors.affiliation: Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Fermo
authors.affiliation: Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Binda
authors.affiliation: Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Santambrogio
authors.affiliation: Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Bucelli
authors.affiliation: Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy.
authors.forename: Agostino
authors.initials: A
authors.lastname: Cortelezzi
mesh_terms: D001549:Benzamides / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000150:complications; D055728:Primary Myelofibrosis / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D009570:Nitriles; D010879:Piperazines; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D000068877:Imatinib Mesylate
keywords: chronic myeloid leukemia; imatinib; myelofibrosis; post-polycythemia vera; ruxolitinib